We found that diffuse EZH2 immunoreactivity was highly specific for thymic carcinoma versus type A thymoma and MNTLS but not type B3 thymoma, whereas the absence of EZH2 immunoreactivity could help to exclude carcinoma. This evidence concerns the gene EZH2 and thymic carcinoma.